Stock data
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX) reported net income of -US$35.17M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$38.11M | -US$35.17M | — |
| 2024 | — | — | -US$56.79M | -US$51.32M | — |
| 2023 | — | — | -US$69.64M | -US$64.73M | — |
| 2022 | — | — | -US$42.26M | -US$40.96M | — |
| 2021 | — | — | -US$21.57M | -US$21.54M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$8.19M | — |
| 2026-03-31 | — | -US$10.03M | — |
| 2025-12-31 | — | -US$8.71M | — |
| 2025-09-30 | — | -US$9.35M | — |
| 2025-06-30 | — | -US$6.46M | — |
| 2025-03-31 | — | -US$10.65M | — |
| 2024-12-31 | — | -US$7.52M | — |
| 2024-09-30 | — | -US$12.75M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.